Skip to Content
Merck
  • Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.

Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.

PloS one (2011-09-15)
Karianne Risberg, Øystein Fodstad, Yvonne Andersson
ABSTRACT

In cancer, combinations of drugs targeting different cellular functions is well accepted to improve tumor control. We studied the effects of a Pseudomonas exotoxin A (PE)-based immunotoxin, the 9.2.27PE, and the BH-3 mimetic compound ABT-737 in a panel of melanoma cell lines. The drug combination resulted in synergistic cytotoxicity, and the cell death observed was associated with apoptosis, as activation of caspase-3, inactivation of Poly (ADP-ribose) polymerase (PARP) and increased DNA fragmentation could be prevented by pre-treatment with caspase and cathepsin inhibitors. We further show that ABT-737 caused endoplasmic reticulum (ER) stress with increased GRP78 and phosphorylated eIF2α protein levels. Moreover, treatment with ABT-737 increased the intracellular calcium levels, an effect which was enhanced by 9.2.27PE, which as a single entity drug had minimal effect on calcium release from the ER. In addition, silencing of Mcl-1 by short hairpin RNA (shRNA) enhanced the intracellular calcium levels and cytotoxicity caused by ABT-737. Notably, the combination of 9.2.27PE and ABT-737 caused growth delay in a human melanoma xenograft mice model, supporting further investigations of this particular drug combination.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Staurosporine from Streptomyces sp., ≥98% (HPLC), film
Sigma-Aldrich
Cycloheximide, from microbial, ≥94% (TLC)
Sigma-Aldrich
Caspase-3 Inhibitor II, The Caspase-3 Inhibitor II, also referenced under CAS 210344-95-9, controls the biological activity of Caspase-3. This small molecule/inhibitor is primarily used for Cancer applications.
Sigma-Aldrich
Cycloheximide solution, Ready-Made Solution, microbial, 100 mg/mL in DMSO, Suitable for cell culture